These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 38374113)

  • 21. Pathological response and clinical outcomes in operable triple-negative breast cancer with cisplatin added to standard neoadjuvant chemotherapy.
    Georgy JT; Singh A; John AO; Joel A; Andrews AG; Thumaty DB; Rebekah G; Sigamani E; Chandramohan J; Manipadam MT; Cherian AJ; Abraham DT; Paul MJ; Balakrishnan R; Backianathan S; Chacko RT
    Klin Onkol; 2021; 34(1):49-55. PubMed ID: 33657819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders.
    Lin PH; Tseng LM; Lee YH; Chen ST; Yeh DC; Dai MS; Liu LC; Wang MY; Lo C; Chang S; Tan KT; Chen SJ; Kuo SH; Huang CS
    J Formos Med Assoc; 2022 Dec; 121(12):2538-2547. PubMed ID: 35752529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Choudhery S; Gomez-Cardona D; Favazza CP; Hoskin TL; Haddad TC; Goetz MP; Boughey JC
    Acad Radiol; 2022 Jan; 29 Suppl 1(Suppl 1):S145-S154. PubMed ID: 33160859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Wang Q; Li C; Tang P; Ji R; Chen S; Wen J
    Cell Physiol Biochem; 2018; 48(6):2539-2548. PubMed ID: 30121642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.
    Asano Y; Kashiwagi S; Onoda N; Noda S; Kawajiri H; Takashima T; Ohsawa M; Kitagawa S; Hirakawa K
    Ann Surg Oncol; 2016 Apr; 23(4):1104-10. PubMed ID: 26511266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer.
    Fisher TB; Saini G; Rekha TS; Krishnamurthy J; Bhattarai S; Callagy G; Webber M; Janssen EAM; Kong J; Aneja R
    Breast Cancer Res; 2024 Jan; 26(1):12. PubMed ID: 38238771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA.
    Chen JH; Addanki S; Roy D; Bassett R; Kalashnikova E; Spickard E; Kuerer HM; Meas S; Sarli VN; Korkut A; White JB; Rauch GM; Tripathy D; Arun BK; Barcenas CH; Yam C; Sethi H; Rodriguez AA; Liu MC; Moulder SL; Lucci A
    BMC Cancer; 2024 Aug; 24(1):1016. PubMed ID: 39148033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
    Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
    FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer.
    Chae S; Kang KM; Kim HJ; Kang E; Park SY; Kim JH; Kim SH; Kim SW; Kim EK
    Curr Oncol; 2018 Apr; 25(2):e113-e119. PubMed ID: 29719435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
    Akashi-Tanaka S; Watanabe C; Takamaru T; Kuwayama T; Ikeda M; Ohyama H; Mori M; Yoshida R; Hashimoto R; Terumasa S; Enokido K; Hirota Y; Okuyama H; Nakamura S
    Clin Breast Cancer; 2015 Feb; 15(1):80-5. PubMed ID: 25445419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Jung HH; Kim JY; Cho EY; Lee JE; Kim SW; Nam SJ; Park YH; Ahn JS; Im YH
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
    Liu L; Li XR; Hu YH; Zhang J
    Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(12):940-3. PubMed ID: 27045718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
    Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.
    Filho OM; Stover DG; Asad S; Ansell PJ; Watson M; Loibl S; Geyer CE; Bae J; Collier K; Cherian M; O'Shaughnessy J; Untch M; Rugo HS; Huober JB; Golshan M; Sikov WM; von Minckwitz G; Rastogi P; Maag D; Wolmark N; Denkert C; Symmans WF
    JAMA Oncol; 2021 Apr; 7(4):603-608. PubMed ID: 33599688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
    Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
    Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.
    Axelrod ML; Nixon MJ; Gonzalez-Ericsson PI; Bergman RE; Pilkinton MA; McDonnell WJ; Sanchez V; Opalenik SR; Loi S; Zhou J; Mackay S; Rexer BN; Abramson VG; Jansen VM; Mallal S; Donaldson J; Tolaney SM; Krop IE; Garrido-Castro AC; Marotti JD; Shee K; Miller TW; Sanders ME; Mayer IA; Salgado R; Balko JM
    Clin Cancer Res; 2020 Nov; 26(21):5668-5681. PubMed ID: 32826327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy.
    Wu K; Yang Q; Liu Y; Wu A; Yang Z
    World J Surg Oncol; 2014 Apr; 12():95. PubMed ID: 24731479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy and survival outcomes of dose-dense carboplatin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer].
    Liu Y; Xiu M; Wang X; Li Q; Wang JY; Fan Y; Li Q; Chen SS; Cai RG; Mo HN; Ma F; Luo Y; Xu BH; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):178-184. PubMed ID: 35184463
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy.
    Guestini F; Ono K; Miyashita M; Ishida T; Ohuchi N; Nakagawa S; Hirakawa H; Tamaki K; Ohi Y; Rai Y; Sagara Y; Sasano H; McNamara KM
    Breast Cancer Res Treat; 2019 Jan; 173(2):275-288. PubMed ID: 30306430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
    Ueno T; Kitano S; Masuda N; Ikarashi D; Yamashita M; Chiba T; Kadoya T; Bando H; Yamanaka T; Ohtani S; Nagai S; Nakayama T; Takahashi M; Saji S; Aogi K; Velaga R; Kawaguchi K; Morita S; Haga H; Ohno S; Toi M
    BMC Med; 2022 Apr; 20(1):136. PubMed ID: 35462552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.